glp-1 receptor agonist medicines The New GLP-1 Agonists: A Comprehensive Overview

95%CI 0.421.17), for those who were treated with such agents at enrolment, the HR was as low as 0.23 and statistically significant in the post-hoc testing (95%CI 0.050.97) (Lam et al., 2021)

136,169,170 With the accumulation of more clinical data and the development of new drugs, these treatment options are expected to provide more effective and comprehensive treatment choices for diabetes patients

Cardiac hypertrophy leads to heart failure at the later decompensated stage of the disease process, which is a primary cause of morbidity and mortality

One meta-analysis (April 2025) found no difference in incidence of aspiration (OR 1.04, 95% CI 0.871.25) despite the patients taking GLP-1 RAs having a higher incidence of residual gastric contents

In addition, glucagon like peptide-1 receptor agonists (GLP-1RAs) can be combined with GLP-1Rs, playing the same role as GLP-1

Liraglutide (Saxenda) was one of the earlier forms of longer-lasting GLP-1s and reduces HbA1c (average blood glucose) levels by around 1.3% on average and fasting plasma glucose by 2 mmol/L